MENLO PARK, CA, Octave Bioscience, a company focused on delivering a new standard of care for multiple sclerosis, announced a $30 million Series B Extension funding round.
Octave Bioscience, a company focused on delivering a new standard of care for multiple sclerosis, announced a $30 million Series B Extension funding round with participation from new investors, dRx Capital, Hikma Ventures, and Intermountain Ventures, with existing investors, The Blue Venture Fund, Echo Health Ventures, Section 32, Northpond Ventures, Deerfield Management, Casdin Capital, and Merck Global Health Innovation Fund.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
